Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Leases (2023 - 2026)

Prelude Therapeutics' Current Leases history spans 4 years, with the latest figure at $2.8 million for Q1 2026.

  • On a quarterly basis, Current Leases rose 6.19% to $2.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 million, a 6.19% increase, with the full-year FY2025 number at $2.7 million, up 10.11% from a year prior.
  • Current Leases hit $2.8 million in Q1 2026 for Prelude Therapeutics, up from $2.7 million in the prior quarter.
  • Over the last five years, Current Leases for PRLD hit a ceiling of $2.8 million in Q1 2026 and a floor of $1.5 million in Q4 2023.
  • Historically, Current Leases has averaged $2.4 million across 4 years, with a median of $2.5 million in 2024.
  • Biggest five-year swings in Current Leases: surged 68.26% in 2024 and later increased 6.19% in 2026.
  • Tracing PRLD's Current Leases over 4 years: stood at $1.5 million in 2023, then soared by 68.26% to $2.5 million in 2024, then increased by 10.11% to $2.7 million in 2025, then increased by 0.62% to $2.8 million in 2026.
  • Business Quant data shows Current Leases for PRLD at $2.8 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.